Currently, three directions are being advocated to address IFNγ-driven resistance to ICBT33: (1) augmenting tumour antigen presentation, (2) inhibiting the action of T cell inhibitory receptors (TCIRs), or (3) increasing TNF signalling in tumours. Here, TNF is linked to neoplasm.